Viral vector-based vaccine: Some of the FAP-targeting preclinical studies show extensive lethal bone, cachexia and anemia that would caution against the clinical development of systemic FAP-targeted treatments (111, 112). This evidence concerns the gene FAP and anemia (phenotype).